ATE361072T1 - N-acetyl-l-pipecolic säure als promoter der produktion des neurotrophischen faktors - Google Patents

N-acetyl-l-pipecolic säure als promoter der produktion des neurotrophischen faktors

Info

Publication number
ATE361072T1
ATE361072T1 AT03754096T AT03754096T ATE361072T1 AT E361072 T1 ATE361072 T1 AT E361072T1 AT 03754096 T AT03754096 T AT 03754096T AT 03754096 T AT03754096 T AT 03754096T AT E361072 T1 ATE361072 T1 AT E361072T1
Authority
AT
Austria
Prior art keywords
acetyl
disease
neurotrophic factor
pipecolic acid
factor production
Prior art date
Application number
AT03754096T
Other languages
English (en)
Inventor
Shoei Furukawa
Atsumi Nitta
Original Assignee
Astellas Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Pharma Inc filed Critical Astellas Pharma Inc
Application granted granted Critical
Publication of ATE361072T1 publication Critical patent/ATE361072T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT03754096T 2002-10-15 2003-10-10 N-acetyl-l-pipecolic säure als promoter der produktion des neurotrophischen faktors ATE361072T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2002300247 2002-10-15

Publications (1)

Publication Number Publication Date
ATE361072T1 true ATE361072T1 (de) 2007-05-15

Family

ID=32104978

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03754096T ATE361072T1 (de) 2002-10-15 2003-10-10 N-acetyl-l-pipecolic säure als promoter der produktion des neurotrophischen faktors

Country Status (11)

Country Link
US (1) US20050282865A1 (de)
EP (1) EP1552834B1 (de)
JP (1) JPWO2004035053A1 (de)
KR (1) KR20050071510A (de)
CN (1) CN1319530C (de)
AT (1) ATE361072T1 (de)
AU (1) AU2003272985A1 (de)
CA (1) CA2500417A1 (de)
DE (1) DE60313643D1 (de)
TW (1) TW200412951A (de)
WO (1) WO2004035053A1 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7273621B2 (en) * 2000-04-05 2007-09-25 Taiyo Kagaku Co., Ltd. Compositions for promoting sleep
JP2007262017A (ja) * 2006-03-29 2007-10-11 Ajinomoto Co Inc ピペコリン酸含有抗糖尿病組成物
JP2012197229A (ja) * 2009-07-28 2012-10-18 Univ Of Tokyo 筋萎縮性側索硬化症の予防及び治療のための医薬
RU2470302C1 (ru) * 2011-09-21 2012-12-20 Государственное бюджетное образовательное учреждение высшего профессионального образования "Пермская государственная медицинская академия имени академика Е.А. Вагнера" Министерства здравоохранения и социального развития Российской Федерации Способ прогнозирования когнитивных нарушений в отдаленном периоде черепно-мозговой травмы

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5798355A (en) * 1995-06-07 1998-08-25 Gpi Nil Holdings, Inc. Inhibitors of rotamase enzyme activity
US5696135A (en) * 1995-06-07 1997-12-09 Gpi Nil Holdings, Inc. Inhibitors of rotamase enzyme activity effective at stimulating neuronal growth
US5801197A (en) * 1995-10-31 1998-09-01 Gpi Nil Holdings, Inc. Rotamase enzyme activity inhibitors
US6323215B1 (en) * 1999-07-09 2001-11-27 Ortho-Mcneil Pharmaceutical, Inc. Neurotrophic tetrahydroisoquinolines and tetrahydrothienopyridines, and related compositions and methods

Also Published As

Publication number Publication date
CA2500417A1 (en) 2004-04-29
CN1694702A (zh) 2005-11-09
US20050282865A1 (en) 2005-12-22
AU2003272985A1 (en) 2004-05-04
DE60313643D1 (de) 2007-06-14
EP1552834A1 (de) 2005-07-13
EP1552834A4 (de) 2006-01-04
EP1552834B1 (de) 2007-05-02
KR20050071510A (ko) 2005-07-07
WO2004035053A1 (ja) 2004-04-29
TW200412951A (en) 2004-08-01
CN1319530C (zh) 2007-06-06
JPWO2004035053A1 (ja) 2006-02-09

Similar Documents

Publication Publication Date Title
PT2527315E (pt) Compostos, composições e métodos para o tratamento de doenças da amiloide e sinucleínopatias tais como doença de alzheimer, diabetes do tipo 2, e doença de parkinson
MXPA02011373A (es) Derivados de triazol.
GB0117326D0 (en) Napthoquinone-type inhibitors of protein aggregation
CA2501799A1 (en) Pyrazole compounds for treatment of neurodegenerative disorders
MXPA04005444A (es) Ureas de 2-aminobenzotiazoles como moduladores de adenosina.
MXPA05002420A (es) Compuestos de tiazol para el tratamiento de trastornos neurodegenerativos.
HK1100426A1 (en) Thiadiazolidinones as gsk-3 inhibitors
GB0318447D0 (en) Therapeutic agents
AU2001273574A1 (en) Substituted 5-alkynyl pyrimidines having neurotrophic activity
MX2011011477A (es) Derivados de isoxazol-piridazina.
UA83691C2 (ru) Применение замещенных 2-аминотетралинов для упреждающего лечения болезни паркинсона
HUP0302478A2 (hu) Modafinil-vegyületek gyógyszerészeti oldatai
MXPA05012391A (es) Tratamiento de trastornos psicoticos y depresivos.
CA2498291A1 (en) Diazabicyclic compounds useful in the treatment of cns and other disorders
MXPA05013628A (es) Pirazolo[3,4-b]piridin-6-onas como inhibidores de gsk-3.
WO2004055201A3 (en) Cholesterol 24-hydroxylase (cyp46) as therapeutic target for the treatment of alzheimer's disease
EP0855391A4 (de) Isochinolderivate
HK1104280A1 (en) Derivatives of 1-phenylalkanecarboxylic acids for the treatment of neurodegenerative diseases
NO20015668L (no) Substituerte imidazotiazoler som antidepressive midler
EP1958939A3 (de) Pyrazolaminverbindungen zur Behandlung neurodegenerativer Erkrankungen
DE60313643D1 (de) N-acetyl-l-pipecolic säure als promoter der produktion des neurotrophischen faktors
WO2005097114A3 (en) Thiazole sulfonamide compounds for the treatment of neurodegenerative disorders
AU2003273310A1 (en) Substituted aminoethers for the treatment of alzheimer's disease
AU2003299101A1 (en) Compounds for the treatment of alzheimer's disease
WO2003000269A3 (de) Neue verwendung für pde 10a-inhibitoren

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties